• Home
  • News
    • Editorial
    • MD(e)B(unker)
    • Related Researches
      • Di Bella's Foundation
      • 1960-1969
      • 1970-1979
      • 1980-1989
      • 1990-1999
      • 2000-2009
      • 2010-2019
      • 2020-2029
    • Science news
    • Scientific Documentation
  • About us...
    • Biography
    • Bibliography
  • The Method
    • Di Bella's Method!
    • 1998 Trial!
  • Media
    • Video Publications
    • News-PapersNews-Papers
      • Press
    • TestimonialTestimonial
      • Testimonies
    • Video GalleryVideo Gallery
      • Congresses
      • Video Testimonies
      • TV & C.
  • Case History
    • Medical reports
      • Lung
      • Lymphomas
        • Non-Hodgkin Lymphomas
        • Hodgkin Lymphomas
      • Mediastinum
      • Mesothelioma
      • Myeloma
      • Pancreas
      • Scientific Publications
  • F.A.Q.
  • Useful Links
    • User Side
      • Vademecum
    • CouponChief - Resources for Cancer Patients
  • Contact Us
Home page   News   Related Researches   1980-1989  

Paralytic ileus responding to somatostatin therapy: first manifestation of a VIPoma

Print Email
Published on Tuesday, 20 January 2015

Letters to the editor

To the Editor:

Referring to the article on the use of somatostatin in patients with pancreatic islet cell tumors in a recent issue of your journal (i.e. "Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors"), we wish to report a case of a malignant VIPoma of the pancreas presenting as a paralytic ileus that responded to somatostatin therapy.

 



Download the complete article

About this Letter to the Editor.

See also:

- Official Web Site: The Di Bella Method;

- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - Somatostatin, Octreotide, Sandostatin LAR, analogues and/or derivatives);

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.

Search

Follow us...

Latest

  • Tumor-associated macrophages facilitate oral squamous cell carcinomas migration and invasion by MIF/NLRP3/IL-1β circuit: A crosstalk interrupted by melatonin
  • Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors
  • Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination
  • Melatonin attenuates bone cancer pain via the SIRT1/HMGB1 pathway
  • Pretreatment with melatonin protects against cyclophosphamide-induced oxidative stress and renal damage in mice
  • Melatonin Pharmacological Blood Levels Increase Total Antioxidant Capacity in Critically Ill Patients
  • A Review of Biological and Pharmacological Actions of Melatonin: Oxidant and Prooxidant Properties
  • Melatonin as Antioxidant Under Pathological Processes
  • Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage
  • Melatonin as antioxidant, geroprotector and anticarcinogen
  • The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor
  • Does the use of melatonin overcome drug resistance in cancer chemotherapy?
  • Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment
  • Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved
  • Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review
  • Multifaceted Role of Vitamin D in Breast Cancer: A Systematic Review of Genetic and Pathway-Based Mechanisms
  • Multifaceted roles of melatonin in oncology: an insight into its therapeutic potential in cancer management
  • Nocturnal Melatonin Deficiency in Colorectal Cancer: Independent Predictive Value Beyond Sleep Quality

Most Read

  • The Di Bella Method (DBM)
  • About melatonin - 1996
  • All-trans-retinoic acid and cancer
  • Biography
  • The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
  • Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
  • Somatostatin in oncology, the overlooked evidences
  • Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
  • How effective is chemo therapy?
  • Bibliography
  • Complete objective response to biological therapy of plurifocal breast carcinoma
  • Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
  • Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
  • Vademecum
  • Frequently Asked Questions
  • Declaration recommends eliminate the use of Impact factor for research evaluation
  • Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
  • Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer